Infinity to Present Latest IPI-549 Data at Immuno-Oncology Meeting

Infinity to Present Latest IPI-549 Data at Immuno-Oncology Meeting
0
(0)

Infinity Pharmaceuticals announced it will present new pre-clinical and early clinical data from the ongoing Phase 1 clinical trial of IPI-549. The presentations will take place in the second International Cancer Immunotherapy Conference: Translating Science into Survival, to be held Sept. 25-28, in New York.

IPI-549 is an immuno-oncology development candidate that selectively inhibits PI3K-gamma. In preclinical studies, IPI-549 has been shown to inhibit immune-suppressive macrophages within the tumor microenvironment, contrary to what is seen with other immunotherapies, such as checkpoint modulators, that target immune effector cell function more directly.

The presentations will be based on data from the first-in-human, dose-escalation Phase 1/1b study (NCT02637531), which was designed to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of IPI-549 as monotherapy and in combination with the anti-PD-1 immunotherapy Keytruda (pembrolizumab) in patients with advanced solid tumors.

The first presentation is titled “IPI-549-01: A Phase 1/1b first-in-human study of IPI-549, a PI3K-gamma inhibitor, as monotherapy and in combination with an anti-PD1 antibody in subjects with advanced solid tumors” (Poster #B070).

The second presentation is titled “The PI3K-gamma inhibitor, IPI-549, increases antitumor immunity by targeting tumor-associated myeloid cells and remodeling the immune-suppressive tumor microenvironment” (Poster #B032).

According to a press release, both presentations will take place on Sept. 26, from 5:15 to 7:45 p.m., during the poster session.

IPI-549 is still an investigational compound, and has not yet been approved by the U.S. Food and Drug Administration (FDA) or any other health authority. But if/when IPI-549 receives approval it may have the potential to treat a broad range of solid tumors and represents a potentially complementary approach to restoring anti-tumor immunity in combination with other immunotherapies, such as checkpoint inhibitors.

The upcoming conference is organized by the Cancer Research Institute (CRI), the Association for Cancer Immunotherapy (CIMT), the European Academy of Tumor Immunology (EATI), and the American Association for Cancer Research (AACR).

This year’s program will focus on ‘Translating Science into Survival’ and feature talks from more than 60 leaders in cancer immunotherapy worldwide. The conference aims to provide an opportunity for teaching, learning, and networking for all stakeholders (clinicians, scientists and patient advocates) and will offer AMA PRA Category 1 Credit certificates to all participants.

 

Inês holds a PhD in Biomedical Sciences from the University of Lisbon, Portugal, where she specialized in blood vessel biology, blood stem cells, and cancer. Before that, she studied Cell and Molecular Biology at Universidade Nova de Lisboa and worked as a research fellow at Faculdade de Ciências e Tecnologias and Instituto Gulbenkian de Ciência. Inês currently works as a Managing Science Editor, striving to deliver the latest scientific advances to patient communities in a clear and accurate manner.
×
Inês holds a PhD in Biomedical Sciences from the University of Lisbon, Portugal, where she specialized in blood vessel biology, blood stem cells, and cancer. Before that, she studied Cell and Molecular Biology at Universidade Nova de Lisboa and worked as a research fellow at Faculdade de Ciências e Tecnologias and Instituto Gulbenkian de Ciência. Inês currently works as a Managing Science Editor, striving to deliver the latest scientific advances to patient communities in a clear and accurate manner.
Latest Posts
  • Tecentriq and FDA approval
  • Opdivo
  • Opdivo-Cabometyx combo
  • Imfinzi, FDA approval

How useful was this post?

Click on a star to rate it!

Average rating 0 / 5. Vote count: 0

No votes so far! Be the first to rate this post.

As you found this post useful...

Follow us on social media!

We are sorry that this post was not useful for you!

Let us improve this post!

Tell us how we can improve this post?